Please login to the form below

Not currently logged in

Dr Sotirios Stergiopoulos leaves Shire for Ipsen

He becomes the French biopharma’s chief medical officer

Sotirios StergiopoulosIpsen has promoted Dr Sotirios Stergiopoulos from global medical affairs to chief medical officer.

He first joined the French biopharma firm from Baxalta - now Shire - last year, where he served as vice president, head of global medical affairs oncology.

Prior to that, he has held roles including executive medical director, oncology, US medical affairs for Celgene and senior global brand medical director, oncology at Novartis.

He said: “This is an exciting time for Ipsen with significant growth and evolution and together with our experienced leadership team, I look forward to helping our company continue to bring innovative new medicines to our patients.”

Stergiopoulos, who has also previously served as director of medical affairs, oncology for Bayer, is a fellow at the American College of Physicians and a member of the Royal Society of Medicine in the UK.

His new role will see him report to Alexandre Lebeaut, executive vice-president R&D and chief scientific officer of Ipsen, who said: “Stergiopoulos has extensive experience in directing global medical affairs strategies and a strong expertise in oncology drug development that includes chemotherapy, immunology drugs and targeted agents across various tumour indications.

“We are delighted to appoint him to an expanded role through which he will make the voice of the patient heard at the highest levels of the organisation and represent the company externally as its primary medical representative.”

2nd February 2018

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge